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We examined the effect of different invitational policies on the reduction of breast cancer mortality at 60–79 years of age within the
Finnish mammography programme in 1992–2003, which varied in its coverage at 60–69 years of age. The data from 260
municipalities were grouped into three categories: regular invitations at 50–59 years of age only, regular invitations at 50–69 years of
age, and regular invitations at 50–59 years of age with irregular invitations at 60–69 years of age. Observed deaths from breast
cancer were compared to those expected without screening among all women and among the screened and non-screened women.
Observed deaths were obtained from population data and from a cohort follow-up in 1992–2003. Expected deaths were derived by
modelling breast cancer mortality at population level in 1974–1985 and 1992–2003. The reduction in breast cancer mortality was
strongest, 28% (0.72, 0.51–0.97), in municipalities with regular invitations at 50–69 years of age. No overall effect at 60–79 years of
age was observed with regular invitations at 50–59 years of age. The study confirms a reduction by screening of breast cancer
mortality in Finland. Uniform extension of invitations to 60–69 years of age would increase the number of prevented breast cancer
deaths among the elderly.
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Randomised trials of mammography screening have shown that
invitation to screening is associated with reduction in breast
cancer mortality. An overview of the Swedish randomised trials
found a significant 21% reduction among women aged 40–74
years at entry, with the greatest reduction of 33% among those
aged 60–69 years at entry (Nystro ¨m et al, 2002).
After randomised trials, mammography screening has been
delivered routinely in several European countries, with emphasis
on monitoring the mortality reduction within service screening.
Results from Denmark, Sweden, and Finland showed that
organised mammography has been effective in reducing breast
cancer mortality among screening invitees and participants (Olsen
et al, 2005; SOSSEG, 2006; Sarkeala et al, 2008). The overall
reduction in breast cancer mortality in Finland was concentrated
at the age group of 50–69 years at death, while in other European
countries it was evident at 50–79 years of age.
There has been a marked variation in the invitational age among
the municipalities within service screening in Finland: the overall
invitational coverage has been over 95% in women aged 50–59
years, but 40% in those aged 60–64 years, and only 20% in those
aged 65–69 years (Sarkeala et al, 2004). Finland, therefore,
provides an opportunity among 60- to 69-year-old invitees for
investigating the effect of organised screening independent of
other changes in health care.
We examined the consequences of different invitational policies
in organised mammography screening on breast cancer mortality
among women aged 60 years or more, together with the mortality
patterns among screened and non-screened women.
MATERIALS AND METHODS
The population-based breast cancer-screening programme in
Finland was initiated in 1987 with a group-randomised design
(Hakama et al, 1997). In 1992, all women aged 50–59 years were
covered and a Bylaw on Public Health was announced. The law
entitled Finnish municipalities to invite women aged 50–59 years
to free mammography screening every second year; for those aged
60–69 years, the screening remained optional. The outcome of
this decision was a wide variation in the invitational coverage of
organised mammography screening at 60–69 years of age.
For the current study, we checked all registered data on biannual
invitations to the screening programme in 1992–2003. The only
screening providers sending information regularly to the Mass
Screening Registry were centres of the Cancer Society of Finland
(CSF), covering 260 municipalities, approximately 50% of all
activities of the population-based mammography in Finland in
1992–2003.
We divided the data into three invitational categories:
regular invitations at the age of 50–59 years (regular 50–59),
regular invitations at the age of 50–69 years (regular 50–69), and
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yregular invitations at the age of 50–59 years with irregular
invitations at 60–69 years of age (irregular 50–69). The
categorisation was based on all available information on invita-
tions in the CSF municipalities in 1992–2003.
These data were available at the individual level. Some CSF
municipalities also sent invitations to self-paid mammography for
60- to 69-year-old women in the study period. The data on these
biannual invitations with a fee were derived at municipal level
from the archives on invited birth cohorts from the Mass
Screening Registry.
Most of the CSF municipalities (216) invited 50- to 59-year-old
women regularly and 60- to 69-year-old women irregularly to
mammography screening in 1992–2003. In these municipalities,
only part of women aged 60–69 years received invitations to
biannual screening throughout the study period. Eight municipa-
lities invited 50- to 69-year-old women regularly, while 36 restricted
their invitations to 50- to 59-year-old women in 1992–2003.
We investigated the impact of different invitational policies on
breast cancer mortality among whole female population and
among screened and non-screened women in the age group of
60–79 years at death in 1992–2003. The observed breast cancer
deaths with screening were compared with the expected breast
cancer deaths without screening. The person-years and the
observed deaths for the whole female population were derived
from population level data. The population data consisted of the
number of women and deaths from breast cancers at 60–79 years
of age in 1992–2003. The breast cancers had been diagnosed at the
age of 50 years or more in 1992–2003. The person-years and the
observed deaths for the screened women were obtained from a
cohort of screening invitees. The data consisted of person-years
and deaths from breast cancer at 60–79 years of age from the
individual follow-up. The breast cancers had been diagnosed
during the follow-up at the age of 50 years or more. The entry date
for the follow-up was 1 January in the first invitation year in 1992–
2003. The exit date was the date of death, the date of emigration,
or 31 December 2003. The screened women were those who had
been invited at least once to any of the screening centres of the CSF
and who had participated after their first invitation in the study
period. Detailed description on the formulation of cohort was
given in a previous study (Sarkeala et al, 2008).
The person-years and the observed deaths for the non-screened
women were obtained by subtracting the figures of the screened
women from those of the whole female population. The group
‘non-screened’ thus contained the non-participants and the non-
invitees of organised mammography screening within the CSF
centres in 1992–2003.
The expected deaths without screening were derived by multi-
plying the expected breast cancer mortality rates without screening
with the corresponding person-years at risk. As non-invited
controls were not available, the expected breast cancer mortality
rates without screening were estimated by modelling, using
population data from 1974 to 1985 and from 1992 to 2003. The
population data consisted of the number of women and deaths
from breast cancers at 60–79 years of age in 1974–1985 and
1992–2003. The breast cancers had been diagnosed at the age of 50
years or more in 1974–1985 and in 1992–2003.
The population data were derived from the Finnish Cancer
Registry and the National Population Registry. The individual data
were collected from the Finnish Mass Screening Registry and
were linked with the data from the Finnish Cancer Registry
and the National Population Registry using a personal identifier
as a key.
The population data from 1975 to 1985 and from 1992 to 2003
were used to estimate the expected mortality rates without
screening in 1992–2003. The period 1974–1985 represented the
latest possible prescreening era of equal length to the screening
period 1992–2003: some CSF municipalities had started screening
1 year before the launch of the national programme.
Expected breast cancer mortality rates among the whole female
population and among the screened and non-screened women
were modelled by Poisson regression with a logarithmic link
function. Five-year age groups at death (60–64, 65–69, 70–74,
75–79), policy categories (regular 50–59, regular 50–69, irregular
50–69), and calendar time within the two periods (1, 2,y,12
years) were used as explanatory variables in both models. For the
entire female population, the period before (1974–1985) and with
screening (1992–2003) by 10-year age groups at death was
included in the model. In the model for screened and
non-screened women, the period before (1974–1985) and with
screening (1992–2003) by 5-year age groups at death and
screening indicator (screened, not screened) were included.
Models are described in detail in Appendix.
The average, category-specific difference in breast cancer
mortality between the two 12-year periods (1974–1985 and
1992–2003) among the whole female population (model 1), and
between the screened and non-screened women (model 2),
represented the screening effect. The fitted mortality values of
the model were calculated after excluding the screening effect,
representing the expected breast cancer mortality rates without
screening. Further details are presented in Appendix.
The confidence intervals of the effect estimates (observed with
screening in 1992–2003/expected without screening in 1992–2003)
were corrected with overdispersion constants produced by the two
models (1.39/1.25). The bias due to self-selection among screened
women was adjusted by a described by Cuzick and co-workers
method (Cuzick et al, 1997).
RESULTS
In 1992–2003, there were altogether 2388775 person-years in the
age group 60–79 (Table 1). The overall reduction in breast
cancer mortality in the age group of 60–79 years at death was
15% (relative risk 0.85, 95% confidence interval 0.77–0.93). In
municipalities that had invited 50- to 69-year-old women regularly,
the breast cancer mortality reduced by 28% (0.72, 0.51–0.97)
(Table 2). The strongest reduction (32%) was estimated in the age
group of 70–79 years at death. In municipalities that had invited
women aged 50–59 years only, no overall reduction in breast
cancer mortality at 60–79 years of age could be observed.
Almost 80% of person-years in the study were accumulated from
municipalities that had invited 50- to 59-year-old women regularly
Table 1 Number of municipalities and person-years at risk among all female population, and among screened and non-screened women in each policy
category in 1992–2003
Person-years
Policy category Number of municipalities All women Screened Non-screened
Regular 50–59 36 256548 86769.2 169778.8
Regular 50–69 8 228527 195139.3 33387.7
Irregular 50–69 216 1903700 741689.2 1162010.8
All 260 2388775 1023597.7 1365177.3
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yand 60- to 69-year-old women irregularly to mammography
screening (Table 1). In this invitational category, the overall
reduction in breast cancer mortality in the age group of 60–79
years at death was 16% (0.84, 0.75–0.92) (Table 2). The reduction
was strongest (24%) in the age group of 60–69 years at death. The
overall effect estimates of municipalities inviting 50- to 69-year-old
women regularly or irregularly differed significantly from those of
the invitational category ‘regular 50–59’ (P¼0.003).
In the cohort of screened women, there were altogether 1023598
person-years during the follow-up (Table 1). A reduction in breast
cancer mortality was observed in all invitational categories
(Table 3). In municipalities that invited women aged 50–59 years
regularly, the reduction could be observed in the age group of
60–69 years at death. In municipalities that invited women aged
50–69 years, the reduction was observed in the age group of 60–79
at death. The non-adjusted relative risk was 0.62 (0.34–0.99) and
adjusted relative risk was 0.67 (0.34–0.99). Owing to widespread
non-registered screening with a customer fee in municipalities
offering irregular screening at 60–69 years of age, the overall
relative risk among the non-screened was slightly below 1, leading
to overestimations in adjusted efficacy estimates of the women in
this category.
Table 2 Observed and expected numbers of breast cancer deaths, and effect estimates with 95% CIs among all women by policy categories in
1992–2003
Regular 50–59 Regular 50–69 Irregular 50–69
60–69 at death
Observed 53 35 282
Expected 52.6 45.8 371.6
Observed/expected (95% CI) 1.01 (0.66–1.44) 0.76 (0.45–1.19) 0.76 (0.64–0.89)
70–79 at death
Observed 78 40 446
Expected 73.2 58.8 499.3
Observed/expected (95% CI) 1.07 (0.76–1.44) 0.68 (0.42–1.03) 0.89 (0.78–1.01)
60–79 at death
Observed 131 75 728
Expected 125.8 104.5 871
Observed/expected (95% CI) 1.04 (0.81–1.31) 0.72 (0.51–0.97) 0.84 (0.75–0.92)
CI, confidence interval.
Table 3 Observed and expected numbers of breast cancer deaths, and effect estimates with 95% CIs among screened and non-screened women by
policy categories in 1992–2003
Regular 50–59 Regular 50–69 Irregular 50–69
Screened
60–69 years at death
Observed 30 28 181
Expected 46.0 36.7 269.9
Observed/expected (95% CI) 0.65 (0.39–1.00) 0.76 (0.45–1.19) 0.67 (0.55–0.80)
70–79 years at death
Observed 0 29 29
Expected 0.0 55.7 61.3
Observed/expected (95% CI) 0.00 0.52 (0.31–0.81) 0.47 (0.28–0.73)
60–79 years at death
Observed 30 57 210
Expected 46.0 92.3 331.2
Observed/expected (95% CI) 0.65 (0.39–1.00) 0.62 (0.43–0.85) 0.63 (0.53–0.75)
Non-screened
60–69 years at death
Observed 23 8 101
Expected 15.6 4.8 98.5
Observed/expected (95% CI) 1.48 (0.82–2.40) 1.67 (0.54–3.73) 1.03 (0.79–1.30)
70–79 years at death
Observed 78 13 417
Expected 63.3 8.6 440.0
Observed/expected (95% CI) 1.23 (0.91–1.61) 1.51 (0.66–2.86) 0.95 (0.84–1.07)
60–79 years at death
Observed 101 21 518
Expected 78.9 13.4 538.5
Observed/expected (95% CI) 1.28 (0.99–1.62) 1.57 (0.84–2.61) 0.96 (0.86–1.07)
CI, confidence interval.
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We investigated the impact of organised mammography on breast
cancer mortality by comparing the observed deaths from breast
cancer with screening to those expected without screening within
three invitational policies in the age group of 60–79 years at death
in 1992–2003. The overall reduction in breast cancer mortality was
strongest, 28%, in municipalities that had invited 50- to 69-year-
old women regularly to mammography screening. With regular
invitations at the age of 50–59 years only, no reduction was
observed in the age of 60–79 years at death. Among the screened
women, the overall reduction in breast cancer mortality was at
similar levels in all three invitational categories, but the effect
became evident at different ages.
The data for the effect estimates were derived from the Finnish
Cancer, the National Population, and the Mass Screening
Registries, which covered all the municipalities under study, and
provided reliable data on breast cancer diagnoses and deaths from
breast cancer, as well as complete information on invitations and
visits to the organised programme.
The invitational coverage of mammography screening with a
customer fee was approximately 25% among 60- to 69-year-old
Finnish women in the late 1990s (Saarenmaa et al, 2000). The
proportion of attendees (40–70%) was lower than that in the
organised programme (88–93%) (tabulated data from the Mass
Screening Registry; Sarkeala et al, 2004). Higher socioeconomic
status did not affect attendance (Immonen-Ra ¨iha ¨ et al, 2001).
Individual level information on invitations to mammography
screening associated with a fee was not available in the Mass
Screening Registry. This hampered the investigation of screening
effect, especially in the invitational category ‘irregular 50–69’, and
led to underestimations of the relative risks among the non-
screened women in this policy category. Non-invitational (oppor-
tunistic or diagnostic) mammography, which has so far not been
registered in Finland, could also modify the effect estimates. This
activity was most prevalent at 60–69 years of age in urban
communities without organised screening.
Evidence-based guidelines for current care have been distrib-
uted by the Finnish Medical Society to all professionals via a health
portal (http://www.terveysportti.fi) since 1994, and no systematic
variations in treatment or diagnostic services between the Finnish
municipalities have been reported. The unique organisation of
mammography in Finland thus enabled us to investigate the
impact of screening on breast cancer mortality as a natural
experiment, without other activities in health care influencing the
effect estimates. The overall results, with a clear variation in breast
cancer mortality between the different invitational policies,
confirm the previously addressed impact of organised screening
breast cancer mortality among screening invitees and participants
in Finland (Sarkeala et al, 2008).
The invitational coverage has varied widely among municipa-
lities, Finland. In other European countries, mammography
programmes have covered women aged 50–69 years. In Sweden,
where women aged 40–69 years have been invited regularly to
biannual screening from the beginning of the programme, the
overall reduction in breast cancer mortality among screening
invitees has been higher than in Finland, 27% (SOSSEG, 2006).
In Denmark, with invitations to 50- to 69-year-old women,
the mortality reduction among invitees in the Copenhagen area
was 25% at 50–79 years of age being strongest, 42 and 31% at 70–
74 and 75–79 years of age, respectively (Olsen et al, 2005).
The considerable post-screening follow-up has reduced the
estimated overall screening effect in the age group of 60–69 years
at death in Finland (Sarkeala et al, 2008). In the municipalities
that invited women aged 50–69 years regularly to screening, the
estimates were, however, consistent with those from Denmark at
the age group of 60–79 years at death and from Turku, Finland
(Olsen et al, 2005; Parvinen et al, 2006). The results were also
consistent with previous predictions on breast cancer mortality at
50–69 years of age (Hristova and Hakama, 1997).
Few municipalities invited only 50- to 59-year-old women to
biannual mammography screening in the study period 1992–2003.
Instead, most had invited women aged 50–59 years regularly and
those aged 60–69 years irregularly. Nevertheless, with regular
invitations of women aged 50–69 years in the study period, the
additional number of breast cancer deaths prevented at 60–79
years of age would have been approximately 140 in the
municipalities under study. Uniform extension of invitations
would thus almost have doubled the number of prevented breast
cancer deaths at 60–79 years of age (see Table 2).
Since 1992, the age limits of organised breast cancer screening
have been subject to a continuous debate in Finland. In December
2006, the Ministry of Health Care and Social Welfare of Finland
announced a Bylaw on Screening to extend the invitational age
from 50–59 to 50–69 years, the expansion to be done gradually:
in 2007, the women born in 1947 will be invited. Thereafter, all
younger birth cohorts will receive a personal invitation to free-of-
charge mammography screening every second year until 69 years
of age. Our findings suggest that this gradual expansion of
invitations will increase the overall number of prevented breast
cancer deaths at 60–79 years of age, but that the annual increase
will remain rather small. The cost-effectiveness of this expansion is
difficult to measure because no baseline estimates on the cost-
effectiveness of opportunistic screening in women in the age group
of 60–69 years exist.
Our results confirm the impact of organised mammography
screening on breast cancer mortality in Finland. Uniform
extension of invitations to women aged 60–69 years, as
recommended on the basis of randomised trials, will increase the
number of deaths prevented at 60–79 years of age.
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APPENDIX
The following definitions were made for the models. Let i¼1, 2, 3, 4
denote the categorical variable 5-year age group at death (60–64,
65–69, 70–74, 75–79), P¼1, 2, 3 denote the categorical variable
screening policy (regular at 50–59 years of age, regular at 50–69
years of age, irregular at 50–69 years of age), y denote the numerical
variable calendar year of death, and n¼1, 2,y,12 denote the
numerical variable calendar time in years since the beginning of the
two periods (1974–1985 and 1992–2003). In the period 1974–1985,
the variable n¼y 1973, and in the period 1992–2003, n¼y 1991.
Thus, n is a function of y, that is, n¼n(y).
Let us define further the categorical screening effect variable
k¼1, 2, 3 for the whole female population for model 1: k¼1i n
the calendar period 1974–1985, k¼2 in the calendar period
1992–2003 for the age group 60–69 (i¼1, 2), and k¼3 in the
calendar period 1992–2003 for the age group 70–79 (i¼3, 4). Let
us also define the categorical screening effect variable s¼1,y,9
for the screened and non-screened women for model 2: s¼1i nt h e
calendar period 1974–1985, s¼2, 3, 4, 5 for i¼1, 2, 3, 4 in the
calendar period 1992–2003 for the non-screened women, and
s¼6, 7, 8, 9 for i¼1, 2, 3, 4 in the calendar period 1992–2003 for
the screened women.
Among the entire female population, the model for the
incidence-based mortality mipy in the age group i, in the policy
category p, and in the calendar year y can then be written as
log(mipy)¼aþbiiþgn(y)þdiin(y)þeppþzkkþZpkpk (model 1).
Among the screened and non-screened women, the model for the
incidence-based mortality is expressed as log(mipys)¼aþbiiþ
gn(y)þdiin(y)þeppþzssþeppþzssþZpsps (model 2).
The interactions in(y), pk, and ps were included in the two
models due to their statistical significance (in(y)) or due to the
question of interest (pk or ps).
Expected breast cancer mortality rates without screening for
the calendar period 1992–2003 were estimated by excluding the
variables related to the screening effects, that is, by using
exp(aþbiiþgn(y)þdiin(y)þepp) with the estimates from the
respective models.
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